【ChiCTR-IIR-17011735】Single shot versus continuous saphenous nerve block for postoperative pain management after total knee replacement: a randomised, double-blind trial
ChiCTR-IIR-17011735
尚未开始
/
/
/
2017-06-22
/
/
Primary osteoarthritis of knee undergoing total knee replacement
Single shot versus continuous saphenous nerve block for postoperative pain management after total knee replacement: a randomised, double-blind trial
Single shot versus continuous saphenous nerve block for postoperative pain management after total knee replacement: a randomised, double-blind trial
852
To investigate and compare the effect of single shot versus continuous saphenous nerve blockade on pain control in the early postoperative period for patients undergoing unilateral primary total knee replacement.
随机平行对照
Ⅳ期
Randomization will be performed by computer program and the results will be sealed in concealed envelops.
/
Departmental funding
/
30
/
2017-10-01
2018-06-30
/
1. Primary, unilateral total knee replacement under central neuroaxial block; 2. Aged 18 to 80 years; 3. American Society of Anesthesiologists (ASA) physical status I – III.；
请登录查看1. Patients with secondary osteoarthritis of the knee; 2. Patients undergoing operation under general anaesthesia; 3. Pregnancy; 4. Body weight < 45 kg or body mass index > 40 kg/m2; 5. Allergy to opioid or local anaesthetics; 6. Patients with contraindications to COX-2 inhibitors use; 7. Chronic opioid use (> 1 month of 60mg morphine oral equivalents daily); 8. Subject refusal.；
请登录查看Department of Anaesthesia and Intensive Care, Pok Oi Hospital
852
Department of Anaesthesia and Intensive Care, Pok Oi Hospital的其他临床试验
Department of Anaesthesia and Intensive Care, Pok Oi Hospital的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验（FIH）成功开展，国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药：超长效靶向TSLP抗体哮喘二期临床取得阳性结果，三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构：国家药品监督管理局 2026-09-10
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构：国家市场监督管理总局 2026-09-18
-
颁布机构：国家市场监督管理总局 2026-09-17
-
颁布机构：国家市场监督管理总局 2026-08-10